A large proportion of drugs available are of little importance in terms of ful¿ lling primary healthcare needs. Combination drugs increase the risk of side effects, lead to an ineffective dosage and liability to abuse and may also needlessly increase the cost. Drug combinations make it more dif¿ cult to ¿ nd the causative agent responsible for the adverse reactions. In many cases their stability is doubtful, reducing the ef¿ cacy of many preparations. The Fifteenth WHO model list of essential medicines (March 2007) contains only 25 approved ¿ xed dose combinations, whereas in Nepal, there are innumerable examples of irrational drug combinations, which are easily available and can be bought even without a prescription. A system of screening the drug combinations that are already licensed and available in the market is implemented in many developed and developing countries. Rational combinations can be of immense help to the health care system. These combinations may improve the quality of life for many and increase compliance. But irrational ¿ xed dose combination products can be equally harmful.
T reating a particular ailment with effective, safe and good quality drugs is the basic aim of drug therapy 1 . It is well documented that safe and effective drug therapy is possible only when patients are well informed about the medications and their use. Irrational drug use can lead to reduction in quality of drug therapy, increased risk of side effects, drug resistance etc 2 . Large proportions of the drugs that are available in the market are of little importance in terms of providing primary healthcare. Prescribing more than one drug for a particular ailment has become a very common practice among physicians. Whether the pharmaceutical manufacturers make the ¿ xed dose combinations (FDCs) because of demand by the physician or physician prescribes multiple drugs because these dosage forms are easily available is a highly debatable issue 1 
.
More than one-third of all the new drug products introduced worldwide during the last decade were ¿ xed dose combination (FDC) preparations. The trend varies from country to country. In Japan, only 10 percent of the new products were FDCs, whereas, in European countries like Spain, it was up to 56 percent 1 . However, such statistical data are not available for the developing countries, but there seems to be a trend towards increasing production and prescription of FDCs. FDCs are available for the treatment of various ailments ranging from nutritional de¿ ciency to cardiovascular diseases. Some combination products may improve the quality of life for many patients. Such combinations (for example, antitubercular and antiretroviral combinations) are essential for many diseases. Many FDC preparations comprise vitamins, cough suppressants, anti-diarrheals, iron preparations, antacids, analgesics and tonics 1 .
There are many popular FDCs in the Nepalese pharmaceutical market, which have À ourished in the last few years. A system of screening the drug combinations that are already licensed and available in the market is implemented in many developed and developing countries 1 . Medical experts worldwide have expressed serious concerns over the increased marketing of drug combinations by pharmaceutical companies, particularly in the developing countries 3 . Most FDCs can impose unnecessary ¿ nancial burden, increased adverse effects, as well as hospitalization, and decreased quality of life 1 . 
What are Fixed

Incidence of Irrational Fixed Dose Combinations use in Nepal
Several studies indicate that Irrational Fixed Dose Combinations (IFDCs) are commonly used in Nepal. Table 2 lists some of these studies. 6, 15 . Table 3 lists some of the commonly used IFDCs in Nepal. The ayurvedic preparations have no any proven ef¿ cacy.
Fixed dose combinations that are approved in National Essential Drug List (NEDL) of Nepal
The latest version of the National Essential Drug List (NEDL) of Nepal approved only a few FDCs. These FDCs are listed in Table 4 . 
FDCs increase the cost of therapy.
Concerning the non-economic, long-term costs of the use of FDCs rather than single-ingredient drugs, one ¿ nds that FDCs cause more harm than good in the long run. Adverse drug reactions and drug interactions are more frequent with FDCs. These reactions and interactions are potentially debilitating and can increase the duration of illness as well as the cost of therapy with FDCs.
Drug resistance;
A more serious concern regarding the use of IFDCs is the emergence of drug resistance to several antibiotics from inappropriate prescription.
Interventions to minimize irrational ¿ xed dose combinations Some interventions that can be carried out to minimize IFDCs are as follows:
Educational interventions: Awareness programs with focus on the deleterious consequences related to the irrational use of medicines should be carried out. All health care professionals should be made aware about the hazards of IFDCs. Educational interventions to improve prescribing for doctors at different levels may be required. Educational sessions, especially for the junior doctors on the impacts of IFDCs should be organized. Mass awareness and education are critical to reduce this trend. Non-governmental organizations can play a role. Doctors prescribing FDCs without diagnostic tests are indulging in a signi¿ cant violation of treatment ethics because they are ignoring the possibilities of harm to the patient from unnecessary medication as well as the long-term public health consequences of such prescriptions. There is a need to strengthen the mechanism for continuing professional development of practitioners to ensure that they have the necessary knowledge and skills to prescribe rationally.
Managerial interventions:
The percentage of drugs prescribed from the essential drug list of Nepal is low. The reason may be related to lack of awareness about the essential drug concept and essential drug list among prescribers. Use of Nepalese National Formulary(NNF) and WHO model formulary should be encouraged.
Prescribing from these formularies can reduce the number of irrational combinations entering the market. It can also reduce the cost spent on drugs. Similarly regular updating of the NNF is also required.
Regulatory interventions: Several literature surveys indicate that the amount of drugs prescribed from the essential drug lists was low. Though the essential drug list was mainly developed for primary health care facilities, prescription of essential drugs should be encouraged. Efforts should be made to develop a hospital formulary based on the concept of essential medicines. Drugs should be prescribed only when genuinely indicated. Similarly the use of FDCs should be discouraged. Guidelines should be developed on the production, sale-distribution and export-import of irrational ¿ xed dose combination products. Direct to consumers advertisements of such drug combinations should also be discouraged and manufacturers should also do adequate research on the rationality of drug combinations before producing and marketing them.
Interventions done in Nepal in relation to ¿ xed dose combinations
The DDA had banned several combination products based on their risk and adverse effects. Banned drug list of DDA includes several combination products. Some of them are listed in Table 5 . 17 .
Conclusion
Rational combinations can be of immense help to the health care system. These combinations may improve the quality of life for many people. Such combinations (for example, antitubercular and antiretroviral combinations) are used frequently for many diseases 18 . However the irrational ¿ xed dose combination products are considered to be equally harmful.
According to the WHO Expert Committee, combination drugs should only be used when there are no alternative of single drugs available for treatment or no alternative single drug is cost-effective for the purpose. Combination drugs increase the risk of side effects and may also needlessly increase the cost. Combination drugs are irrational also because their stability is doubtful, reducing the ef¿ cacy of many preparations 16 . The analysis of reports received by pharmacovigilance centres show that the common reason for adverse drug reactions is irrational use of medicines 19 . One of the main cause of irrational use of medicines may be availability of irrational ¿ xed dose combinations.
Most essential drugs should be formulated as single compounds. Fixed dose ratio combination products are acceptable only when the dosage of each ingredient meets the requirements of a de¿ ned population group and when the combination has a proven advantage over single compounds administered separately in therapeutic effects, safety or compliance 20 .
